Published in Neurology on April 01, 1997
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol (2007) 0.98
MAO-inhibitors in Parkinson's Disease. Exp Neurobiol (2011) 0.97
Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics (2008) 0.94
Depression and Parkinson's disease: current knowledge. Curr Neurol Neurosci Rep (2013) 0.92
Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics (2014) 0.90
Pharmacological treatment of Parkinson's disease. Postgrad Med J (2000) 0.87
Anxiety in Parkinson's disease: identification and management. Ther Adv Neurol Disord (2014) 0.86
The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res (2013) 0.86
Rasagiline in treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.82
Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC Neurol (2011) 0.82
The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder. P T (2008) 0.79
Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis (2015) 0.78
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. J Neural Transm (Vienna) (2007) 0.78
Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ (2006) 0.78
The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging (2010) 0.77
An interesting case of serotonin syndrome precipitated by escitalopram. Indian J Pharmacol (2010) 0.77
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence (2011) 0.77
Role of rasagiline in treating Parkinson's disease: Effect on disease progression. Ther Clin Risk Manag (2009) 0.76
Evaluation and management of the non-motor features of Parkinson's disease. Ther Adv Chronic Dis (2011) 0.75
Successful use of rasagiline in combination with two antidepressants: a case report. Innov Clin Neurosci (2012) 0.75
Mood Disorders in Neurologic Illness. Curr Treat Options Neurol (2000) 0.75
TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell (2001) 4.60
Phase II/III randomized trial of TCH346 in patients with ALS. Neurology (2007) 3.22
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2002) 2.81
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet (1992) 2.39
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol (1997) 2.17
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Management of Parkinson's disease a review of current and new therapies. Can J Neurol Sci (1999) 2.16
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A (2003) 2.15
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology (2002) 1.90
Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord (2002) 1.79
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 1.77
Clinical judgment: how expert nurses use intuition. Am J Nurs (1987) 1.76
Differential expression of immediate early genes in the hippocampus and spinal cord. Neuron (1990) 1.76
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology (2007) 1.68
Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A (1998) 1.64
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Slowly fading super-luminous supernovae that are not pair-instability explosions. Nature (2013) 1.52
Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics. Vet J (2003) 1.48
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol (1994) 1.47
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology (2006) 1.45
The Tourette syndrome diagnostic confidence index: development and clinical associations. Neurology (1999) 1.44
A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet (1999) 1.43
D2 dopamine receptor alleles do not influence severity of Tourette's syndrome. Results from four large kindreds. Arch Neurol (1994) 1.43
Genome-wide association study of Tourette's syndrome. Mol Psychiatry (2012) 1.42
Environmental risk factors in Parkinson's disease. Neurology (1990) 1.39
Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry (2000) 1.36
High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol (1997) 1.36
Multiple autophosphorylation site mutations of the epidermal growth factor receptor. Analysis of kinase activity and endocytosis. J Biol Chem (1991) 1.34
Oral ciprofloxacin versus ceftriaxone for the treatment of urethritis from resistant Neisseria gonorrhoeae in Zambia. Antimicrob Agents Chemother (1990) 1.32
Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N Engl J Med (2000) 1.31
Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology (2000) 1.31
Linkage disequilibrium between an allele at the dopamine D4 receptor locus and Tourette syndrome, by the transmission-disequilibrium test. Am J Hum Genet (1996) 1.29
Reproducible replacement of elongated or ruptured mitral valve chordae. Ann Thorac Surg (1983) 1.29
The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol (1995) 1.29
Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology (2001) 1.25
Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci (1996) 1.24
Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med (1988) 1.23
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology (2001) 1.20
Anisotropic multi-scale fluid registration: evaluation in magnetic resonance breast imaging. Phys Med Biol (2005) 1.20
Presymptomatic neuropsychological impairment in Huntington's disease. Arch Neurol (1988) 1.19
Induction of tolerance to an IgG autoantibody. Proc Natl Acad Sci U S A (1992) 1.19
SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol (1996) 1.19
School problems in Tourette's syndrome. Arch Neurol (1996) 1.16
The natural history of embouchure dystonia. Mov Disord (2001) 1.15
A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology (1997) 1.15
Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med (1995) 1.12
Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology (2007) 1.12
Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology (2003) 1.12
Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry (1999) 1.11
Adult-onset subacute sclerosing panencephalitis: case reports and review of the literature. Mov Disord (1997) 1.11
Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology (2003) 1.09
Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol (1986) 1.08
Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment. J Med Genet (1993) 1.08
Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology (2002) 1.07
Cardiac alpha-myosin heavy chains differ in their induction of myocarditis. Identification of pathogenic epitopes. J Clin Invest (1993) 1.07
Neuroleptic malignant syndrome. Clin Neuropharmacol (1984) 1.07
From beginner to expert: gaining a differentiated clinical world in critical care nursing. ANS Adv Nurs Sci (1992) 1.05
In vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea. Antimicrob Agents Chemother (1990) 1.04
Clues to the aetiological heterogeneity of testicular seminomas and non-seminomas: time trends and age-period-cohort effects. Int J Epidemiol (2000) 1.04
Evidence for atypical depression in Parkinson's disease. Am J Psychiatry (1988) 1.02
Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss muscular dystrophy. Am J Med Genet (2001) 1.02
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord (2005) 1.01
Psychogenic tremors. Neurology (1989) 0.99
MR volumetric analysis of the human basal ganglia: normative data. Acad Radiol (2000) 0.99
Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci (1992) 0.99
Indications of linkage and association of Gilles de la Tourette syndrome in two independent family samples: 17q25 is a putative susceptibility region. Am J Hum Genet (2004) 0.98
Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience (1993) 0.98
Receptor tyrosine kinase-GPCR signal complexes. Biochem Soc Trans (2003) 0.98
SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. Neurology (2002) 0.98
Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation. Clin Genet (2007) 0.97
Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem (2001) 0.96
Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. Ann Neurol (1995) 0.96
Genome scan for linkage to Gilles de la Tourette syndrome. Am J Med Genet (1999) 0.95
Segregation and linkage analyses of Tourette's syndrome and related disorders. J Am Acad Child Adolesc Psychiatry (1990) 0.95
Inhibition of AIDS-associated Kaposi's sarcoma cell growth by DAB389-interleukin 6. AIDS Res Hum Retroviruses (1994) 0.95
Cardiomyopathy in transgenic myf5 mice. Circ Res (1996) 0.95
Primary cardiac neurilemoma. Cancer (1976) 0.95
The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol (1991) 0.94
[Scintigraphically "hot" thyroid nodules mainly go hand in hand with a normal TSH]. Nuklearmedizin (2011) 0.94
Normal cardiovascular development in mice deficient for 16 genes in 550 kb of the velocardiofacial/DiGeorge syndrome region. Proc Natl Acad Sci U S A (2000) 0.93
Counterimmunoelectrophoresis for rapid identification of blood-culture isolates. Am J Clin Pathol (1979) 0.93
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol (2004) 0.93
Survival patterns for the top four cancers in Canada: the effects of age, region and period. Eur J Cancer Prev (2005) 0.93
Familial Tourette's syndrome: report of a large pedigree and potential for linkage analysis. Neurology (1986) 0.92
Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord (1999) 0.91
BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology (2005) 0.90